

INDICATION

SOLIRIS is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.¹

SELECT IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

SOLIRIS, a complement inhibitor, increases the risk of serious infections caused by *Neisseria meningitidis* [see Warnings and Precautions (5.1)]. Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.

- Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks
 prior to the first dose of SOLIRIS, unless the risks of delaying SOLIRIS therapy outweigh the risk of developing
 a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP)
 recommendations for vaccinations against meningococcal bacteria in patients receiving a complement inhibitor.
 See Warnings and Precautions (5.1) for additional guidance on the management of the risk of serious infections
 caused by meningococcal bacteria.
- Patients receiving SOLIRIS are at increased risk for invasive disease caused by Neisseria meningitidis, even
 if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious
 meningococcal infections and evaluate immediately if infection is suspected.

Because of the risk of serious meningococcal infections, SOLIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ULTOMIRIS and SOLIRIS REMS [see Warnings and Precautions (5.2)].

Please see Important Safety Information on pages <u>1-3</u> and accompanying full <u>Prescribing Information</u> for SOLIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.



Product Overview¹

SOLIRIS® (eculizumab) is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.

SOLIRIS is administered as an intravenous (IV) infusion (not as an IV push or bolus injection), lasting about 35 minutes in adults. SOLIRIS is supplied as a 300 mg /30 mL (10 mg/mL) single-dose vial. Infusions for PNH usually occur in a physician office, infusion center, hospital outpatient clinic, or patient home.

SELECT IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

• SOLIRIS is contraindicated for initiation in patients with unresolved serious Neisseria meningitidis infection.

WARNINGS AND PRECAUTIONS

Serious Meningococcal Infections

SOLIRIS, a complement inhibitor, increases a patient's susceptibility to serious, life-threatening, or fatal infections caused by meningococcal bacteria (septicemia and/or meningitis) in any serogroup, including non-groupable strains. Life-threatening and fatal meningococcal infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors.

Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with SOLIRIS. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information.

If urgent SOLIRIS therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible. Various durations and regimens of antibacterial drug prophylaxis have been considered, but the optimal durations and drug regimens for prophylaxis and their efficacy have not been studied in unvaccinated or vaccinated patients receiving complement inhibitors, including SOLIRIS. The benefits and risks of treatment with SOLIRIS, as well as those associated with antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by *Neisseria meningitidis*.

Vaccination does not eliminate the risk of serious meningococcal infections, despite development of antibodies following vaccination.

Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if these signs and symptoms occur. Promptly treat known infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of SOLIRIS in patients who are undergoing treatment for serious meningococcal infection, depending on the risks of interrupting treatment in the disease being treated.

ULTOMIRIS and SOLIRIS REMS

Due to the risk of serious meningococcal infections, SOLIRIS is available only through a restricted program called ULTOMIRIS and SOLIRIS REMS.

Prescribers must enroll in the REMS, counsel patients about the risk of serious meningococcal infection, provide patients with REMS educational materials, assess patient vaccination status for meningococcal vaccines (against serogroups A, C, W, Y, and B) and vaccinate if needed according to current ACIP recommendations two weeks prior to the first dose of SOLIRIS. Antibacterial drug prophylaxis must be prescribed if treatment must be started urgently and the patient is not up to date with both meningococcal vaccines according to current ACIP recommendations at least two weeks prior to the first dose of SOLIRIS. Patients must receive counseling about the need to receive meningococcal vaccines and to take antibiotics as directed, the signs and symptoms of meningococcal infection, and be instructed to carry the Patient Safety Card with them at all times during and for 3 months following SOLIRIS treatment.

Further information is available at www.UltSolREMS.com or 1-888-765-4747.

Please see Important Safety Information on pages <u>1-3</u> and accompanying full <u>Prescribing Information</u> for SOLIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.

SELECT IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Other Infections

Serious infections with *Neisseria* species (other than *Neisseria meningitidis*), including disseminated gonococcal infections, have been reported.

SOLIRIS blocks terminal complement activation; therefore, patients may have increased susceptibility to infections, especially with encapsulated bacteria, such as infections with *Neisseria meningitidis* but also *Streptococcus pneumoniae*, *Haemophilus influenzae*, and to a lesser extent, *Neisseria gonorrhoeae*. Additionally, *Aspergillus* infections have occurred in immunocompromised and neutropenic patients. Children treated with SOLIRIS may be at increased risk of developing serious infections due to *Streptococcus pneumoniae* and *Haemophilus influenzae* type b (Hib). Administer vaccinations for the prevention of *Streptococcus pneumoniae* and *Haemophilus influenzae* type b (Hib) infections according to ACIP recommendations. Patients receiving SOLIRIS are at increased risk for infections due to these organisms, even if they develop antibodies following vaccination.

Monitoring Disease Manifestations After SOLIRIS Discontinuation

Monitor patients after discontinuing SOLIRIS for at least 8 weeks to detect hemolysis.

Thrombosis Prevention and Management

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

Infusion-Related Reactions

Administration of SOLIRIS may result in infusion-related reactions, including anaphylaxis or other hypersensitivity reactions. In clinical trials, no patients experienced an infusion-related reaction which required discontinuation of SOLIRIS. Interrupt SOLIRIS infusion and institute appropriate supportive measures if signs of cardiovascular instability or respiratory compromise occur.

ADVERSE REACTIONS

The most frequently reported adverse reactions in the PNH randomized trial (≥10% overall and greater than placebo) were: headache, nasopharyngitis, back pain, and nausea.

To report SUSPECTED ADVERSE REACTIONS contact Alexion Pharmaceuticals, Inc. at 1-844-259-6783 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full <u>prescribing information</u> for SOLIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.

Please see Important Safety Information on pages <u>1-3</u> and accompanying full <u>Prescribing Information</u> for SOLIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.

Purpose of This Guide and Disclaimer

Alexion Pharmaceuticals, Inc. has developed the SOLIRIS® (eculizumab) Coding and Billing Guide to provide objective and publicly available coding and billing information.

This document is provided for informational purposes only and is not legal advice or official guidance from payers. It is not intended to increase or maximize reimbursement by any payer. Alexion does not warrant, promise, guarantee, or make any statement that the use of this information will result in coverage or payment for SOLIRIS, or that any payment received will cover providers' costs. Alexion is not responsible for any action providers take in billing for, or appealing, SOLIRIS claims.

Hospitals and physicians are responsible for compliance with Medicare and other payer rules and requirements and for the information submitted with all claims and appeals. Before any claims or appeals are submitted, hospitals and physicians should review official payer instructions and requirements, should confirm the accuracy of their coding or billing practices with these payers, and should use independent judgment when selecting codes that most appropriately describe the services or supplies provided to a patient.

Please visit <u>www.SOLIRIS.net</u> for additional information or for inquiries regarding reimbursement, please call 1-888-765-4747 to speak with a OneSource[™] patient support specialist who can connect you with your local Field Reimbursement Manager (FRM). OneSource[™] is available Monday through Friday, 8:30 AM-8 PM EST.

Please see Important Safety Information on pages <u>1-3</u> and accompanying full <u>Prescribing Information</u> for SOLIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.

Coding for SOLIRIS® (eculizumab) in PNH

Diagnosis Coding

The following *International Classification of Diseases*, 10th Revision, Clinical Modification (ICD-10-CM) diagnosis code may be appropriate to describe patients diagnosed with PNH:

ICD-10-CM Diagnosis Code ²	Code Descriptor
D59.5	Paroxysmal nocturnal hemoglobinuria

Drug Coding

The following drug-specific Healthcare Common Procedure Coding System (HCPCS) billing code can be reported on medical claim forms to payers:

HCPCS Code ³	Code Descriptor
J1300	Injection, eculizumab, 10 mg

The following HCPCS modifiers may be required for SOLIRIS, as applicable:

Modifier ³	Description	Commercial Requirement	Medicare Requirement
JZ	Zero drug amount discarded/not administered to any patient	Varies by payer	Υ
JG	Drug or biological acquired with 340B drug pricing program discount, reported for informational purposes	N	Υ
RE	Furnished in full compliance with FDA-mandated risk evaluation and mitigation strategy (REMS)	Υ	Υ
ТВ	Drug or biological acquired with 340B drug pricing program discount, reported for informational purposes for select entities	N	Y

Some payers, including Medicaid, require drugs like SOLIRIS to be billed on medical claims with the product's National Drug Code (NDC) in addition to the HCPCS code. Payers typically require healthcare professionals to use the Health Insurance Portability and Accountability Act (HIPAA)-compliant, 11-digit NDC format⁴:

11-Digit NDC ^{1,4}	Code Descriptor	Strength
25682-0001-01	SOLIRIS eculizumab single-use vial	300 mg/30 mL

Please note that payers have different guidance for placement of the NDC on medical claims. Typically, the 11-digit NDC is reported without any dashes or other punctuation.⁴

Drug Administration Services

Payers may offer separate coverage and reimbursement for drug administration services. The following Current Procedural Terminology (CPT®) codes may be appropriate to report administration of SOLIRIS in physician offices and hospital outpatient facilities. Individual payer policies should be reviewed for reporting requirements:

CPT⁵	Code Descriptor
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to one hour
+ 96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (list separately in addition to code for primary procedure)
96413ª	Chemotherapy administration, intravenous infusion technique, up to one hour, single or initial substance/drug
+ 96415 ^a	Chemotherapy administration, intravenous infusion technique; each additional hour (list separately in addition to code for primary procedure)

a. Billing highly complex administration codes (96413 and 96415) requires the provider in the medical record to document the complexity beyond what is required for therapeutic infusions (96365 and 96366).⁶

Please see Important Safety Information on pages <u>1-3</u> and accompanying full <u>Prescribing Information</u> for SOLIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.

Coding for Meningococcal Vaccination

Diagnosis Coding

For an encounter strictly for the vaccination, the diagnosis code for prophylactic vaccination is assigned along with the diagnosis code for PNH and any other conditions the patient may have.

ICD-10-CM Diagnosis Code ²	Code Descriptor
Z23	Encounter for immunization

Vaccine Coding

Coverage of meningococcal vaccines may vary by payer. Prescribers should consult respective payer billing guidelines.

CPT Code ⁵	Code Descriptor
90619	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use
90620	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2-dose schedule, for intramuscular use
90621	Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2- or 3-dose schedule, for intramuscular use
90733	Meningococcal polysaccharide vaccine, serogroups A, C, Y, W-135, quadrivalent (MPSV4), for subcutaneous use
90734	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use
90749	Unlisted vaccine/toxoid

Vaccine Administration Coding

The following CPT codes may be appropriate to report administration of meningococcal vaccines in outpatient settings:


CPT Code⁵	Code Descriptor
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)
+ 90472	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)

Please see Important Safety Information on pages <u>1-3</u> and accompanying full <u>Prescribing Information</u> for SOLIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.

Claim Forms

Sample CMS-1500 (or the electronic equivalent 837P): Physician Office⁷

For an example of a completed CMS-1500 form, go to page 8.



Please see Important Safety Information on pages <u>1-3</u> and accompanying full <u>Prescribing Information</u> for SOLIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.

Claim Forms

Sample CMS-1500 (or the electronic equivalent 837P): Physician Office⁷

To achieve a SOLIRIS maintenance dose of 900 mg for a patient 18 years of age and

Example claim form for a SOLIRIS® (eculizumab) IV infusion:

older, the following vials were used: • 3 single-use 300 mg/30 mL vials (NDC 25682-0001-01) Item 21 Diagnosis: Enter the appropriate diagnosis code, eg, - ICD-10-CM **D59.5** for paroxysmal nocturnal Item 23 Prior Authorization: hemoglobinuria Enter the prior authorization number assigned by the payer. Note: Other diagnosis codes may apply. 19. ADDITION 2. RESUBMISSION CODE RIGINAL REF. NO. 23. PRIOR AUTHORIZATION NUMBER DATE(S) OF SERVICE PROCEDURES, SERVICES, OR SUPPLIES E. NAGNOSIS G. DAYS OR UNITS J. RENDERING SUPPLIER INFORMATION (Explain Unusual Circumsta MODIFIER MM DD \$ CHARGES SERVICE EMG PROVIDER ID. # POINTER N425682000101 JZ RE 90 J1300 Α XXX XX MM DD YY MM DD YY 11 MM DD YY MM DD YY 96365 Α XXX XX 8 **Item 24E Diagnosis PHYSICIAN** Pointer: Enter the letter (A-L) corresponding to Item 24A Date(s) of Service: Enter Item 24D Procedures/Services/ the diagnosis code in **Supplies:** Enter the appropriate CPT/ the NDC number in the shaded Item 21. area and the month, day, and year HCPCS codes and modifiers, eg, svd for NUCC Use Drug: J1300 for SOLIRIS per 10 mg in the white space below. The "N4" qualifier is required before the Applicable modifiers: • JZ Zero drug amount NDC; do not include dashes. Item 24G Units: Enter the appropriate discarded/not administered number of units of service, eg, SOLIRIS 900 mg Note: Check payer requirements and to any patient is reported with "90" units. format for reporting NDC. • RE Furnished in full compliance with FDAmandated risk evaluation and mitigation strategy (REMS) Administration: 96365 for IV infusion


Please see Important Safety Information on pages <u>1-3</u> and accompanying full <u>Prescribing Information</u> for SOLIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.

Note: Some payers may provide specific

guidance.

Sample CMS-1450 (UB-04) (or the electronic equivalent 837I): Hospital Outpatient Clinic or Facility⁸

For an example of a completed CMS-1450 form, go to page 10.




Please see Important Safety Information on pages <u>1-3</u> and accompanying full <u>Prescribing Information</u> for SOLIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.

Sample CMS-1450 (UB-04) (or the electronic equivalent 837I): Hospital Outpatient Clinic or Facility⁸

Example claim form for a SOLIRIS® (eculizumab) IV infusion:

To achieve a SOLIRIS maintenance dose of 900 mg for a patient 18 years of age and older, the following vials were used:

3 single-use 300 mg/30 mL vials (NDC 25682-0001-01)



Please see Important Safety Information on pages <u>1-3</u> and accompanying full <u>Prescribing Information</u> for SOLIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.





Alexion Access Navigator is a dedicated resource website for US Healthcare Professionals and their offices that contains downloadable access and reimbursement materials for SOLIRIS® (eculizumab).

Online: https://alexionaccessnavigator.com

OneSource™ Offers Patient Support

Contact OneSource

Phone: 1-888-765-4747

Online:

https://alexiononesource.com/

References

- 1. SOLIRIS. Prescribing information. Alexion Pharmaceuticals, Inc.
- 2. Centers for Medicare & Medicaid Services. 2024 ICD-10-CM. Updated April 1, 2024. Accessed May 1, 2024. https://www.cdc.gov/nchs/icd/Comprehensive-Listing-of-ICD-10-CM-Files.htm
- 3. Centers for Medicare & Medicaid Services. July 2024 alpha numeric HCPS file. Accessed May 10, 2024. https://www.cms.gov/files/zip/july-2024-alpha-numeric-hcpcs-file.zip
- 4. Food and Drug Administration. Future format of the National Drug Code; public hearing; request for comments. *Fed Regist*. August 7, 2018. Accessed May 14, 2024. https://www.federalregister.gov/documents/2018/08/07/2018-16807/future-format-of-the-national-drug-code-public-hearing-requestforcomments
- 5. American Medical Association. *PT 2024 Professional Edition*. AMA; 2023. All rights reserved. CPT® is a registered trademark of the American Medical Association.
- 6. Centers for Medicare & Medicaid Services. Billing and coding: complex drug administration coding (A58527). November 26, 2020. Updated April 1, 2024. Accessed May 10, 2024. https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleld=58532&Cntrctr=365&ContrVer=1&CntrctrSelected=365*1&DocType=Active
- National Uniform Claim Committee. 1500 health insurance claim form reference instruction manual for form version 02/12. July 2023. Accessed May 14, 2024. https://www.nucc.org/images/stories/PDF/1500_claim_form_instruction_manual_2023_07-v11.pdf
- Centers for Medicare & Medicaid Services. Medicare claims processing manual chapter 25 completing and processing the form CMS-1450 data set. Updated January 1, 2019. Accessed May 14, 2024. https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c25.pdf
- Noridian Healthcare Solutions. Revenue codes. Updated March 18, 2024. Accessed May 14, 2024. https://med.noridianmedicare.com/web/jea/topics/claim-submission/revenue-codes

Please see Important Safety Information on pages <u>1-3</u> and accompanying full <u>Prescribing Information</u> for SOLIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.

AstraZeneca Rare Disease

ALEXION, the Alexion logo, and SOLIRIS are registered trademarks and OneSource is a trademark of Alexion Pharmaceuticals, Inc. © 2024, Alexion Pharmaceuticals, Inc. All rights reserved.